Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, rand
8 days ago
- #malaria
- #tafenoquine
- #primaquine
- The study compared the effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in treating Plasmodium vivax malaria.
- A multicentre, open-label, randomised, controlled, superiority trial was conducted in Ethiopia, Pakistan, Indonesia, and Cambodia with 960 enrolled patients.
- Primary endpoint was the cumulative incidence of P. vivax parasitaemia within 6 months, comparing the primaquine groups.
- 7-day high-dose primaquine and single-dose tafenoquine showed lower recurrence rates (13.0% and 12.6% respectively) compared to 14-day low-dose primaquine (18.5%).
- Both shorter regimens were well-tolerated, with fewer drug-related adverse events in the tafenoquine group compared to the primaquine groups.
- The study supports the effectiveness and operational feasibility of shorter radical cure regimens in diverse malaria-endemic settings.